BioSpace News Archive

Regeneron Pharmaceuticals, Inc. announced the company will share a range of presentations for its PD-1 inhibitor Libtayo® and broader oncology portfolio at the 2021 American Society of Clinical Oncology Annual Meeting from June 4-8, taking place virtually.

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare, a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, announced the appointment of Mary Ritchie to its Board of Directors.

- Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary

LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting,

Findings to be presented at the ASCO Annual Meeting show preliminary efficacy in patients with EGFR-mutated NSCLC and Janssen’s commitment to address the need for new targeted therapies for this patient population Janssen to also present data comparing amivantamab monotherapy and real-world therapies in patients with NSCLC with EGFR exon 20 insertion mutations who have progressed after platinum doublet chemotherapy

Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released today Two patients who achieved a complete response (CR) remain with no evidence of disease, one for over 24 months and the other for over 14 months on study TK216 remained generally well tolerated with a manageable safety profile

Arena Pharmaceuticals, Inc. announced that on May 15, 2021, the Compensation Committee of its Board of Directors granted to 22 new employees inducement stock options to purchase an aggregate of 74,905 shares of its common stock and 32,050 inducement restricted stock units.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will present results from a study with more than 275,000 women validating the use of a new method for polygenic breast cancer risk assessments in women of all ancestries. The new data will be shared in an oral presentation with leading collaborators on June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2021.